NCT06117813 is a NA clinical trial of Nu.T in Intermittent Exotropia, sponsored by Nunaps Inc.

Who is sponsoring NCT06117813?

NCT06117813 is sponsored by Nunaps Inc.

What drugs are being tested in NCT06117813?

Interventions in NCT06117813: Nu.T, No-Treatment Control.

What condition does NCT06117813 study?

NCT06117813 studies Intermittent Exotropia.

Is NCT06117813 still recruiting?

NCT06117813 is currently completed. Last updated 18 September 2025.

Last reviewed 2025-09-18 · How we verify

NCT06117813

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Visual Perceptual Learning Based Digital Therapeutics for Stereopsis in Intermittent Exotropia

Completed NA Last updated 18 September 2025

What this trial tests

NA trial testing Nu.T in Intermittent Exotropia in 54 participants. Completed in 16 July 2025.

Timeline

22 December 2023

Primary endpoint
12 June 2025

16 July 2025

Quick facts

Lead sponsor	Nunaps Inc
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	54
Start date	22 December 2023
Primary completion	12 June 2025
Estimated completion	16 July 2025
Sites	6 locations across South Korea

Drugs / interventions tested

Nu.T
No-Treatment Control

Conditions studied

Intermittent Exotropia — all drugs for Intermittent Exotropia →

Sponsor

Nunaps Inc

Who can join

Adults 6 to 15, any sex, with Intermittent Exotropia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the efficacy and safety of visual perceptual learning for improving stereopsis in intermittent exotropia. Half of participants will receive visual perceptual training using the Nu.T. The other half will not receive any training because there is no standard treatment for decreased stereopsis in intermittent exotropia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Nunaps Inc trials

Trials by the same sponsor.

NCT06160726 — MRI-based Artificial Intelligence Software (NNS-SOT) for Onset Time Estimation in Lesion With Acute Ischemic Stroke · completed
NCT05525949 — Visual Perceptual Learning Based Digital Therapeutics for Visual Field Defect After Stroke · NA · completed
NCT04102605 — Visual Perceptual Learning for the Treatment of Visual Field Defect · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06117813 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nunaps Inc
Last refreshed: 18 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06117813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing